無料セミナー : 2019年11月19日『手術用ロボット:外科医療におけるトランスフォーメーション』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の癌における精密医療 (プレシジョンメディシン) ITソリューション - 注目企業:2017年

Global Precision Medicine IT Solutions for Oncology - Companies to Action, 2017

発行 Frost & Sullivan 商品コード 596045
出版日 ページ情報 英文 81 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
世界の癌における精密医療 (プレシジョンメディシン) ITソリューション - 注目企業:2017年 Global Precision Medicine IT Solutions for Oncology - Companies to Action, 2017
出版日: 2017年11月24日 ページ情報: 英文 81 Pages
概要

当レポートは、癌向けの精密医療 (プレシジョンメディシン) 領域において有望・破壊的・先駆的なソリューションを提供するベンダーのプロファイルを提供しています。

第1章 エグゼクティブサマリー

第2章 注目企業の概要

  • 産業コンバージェンスが促進する破壊と革新
  • 医療におけるコンバージェンスが機会と脅威の双方を生み出す
  • 注目企業 - 現在の医療産業パラダイムを破壊する可能性

第3章 デジタルヘルス産業のスナップショット

  • 広範な産業コンバージェンスによるデジタルヘルスのメリット
  • デジタルヘルスのプライオリティ
  • デジタルヘルス市場の区分・コンバージェンス

第4章 癌向け精密医療 (プレシジョンメディシン) 市場の概要

  • 精密医療 (プレシジョンメディシン) とは?
  • 市場の課題・機会・懸念事項
  • 精密医療 (プレシジョンメディシン) 導入の現況
  • 精密医療 (プレシジョンメディシン) の主なデータソース
  • 癌における精密医療 (プレシジョンメディシン) の影響
  • 主な市場インフルエンサーの影響
  • 癌向け精密医療 (プレシジョンメディシン) のオペレーショナルアーキテクチャー
  • 癌向け精密医療 (プレシジョンメディシン) のオペレーショナルアーキテクチャーの説明
  • ステークホルダーのデジタルヘルスソリューション
  • 継続的なケア全体に適用されるデジタルヘルスソリューション
  • 癌向け精密医療 (プレシジョンメディシン) をサポートするデジタルヘルス企業:ベンダー情勢
  • 主な産業ニーズ・ベンダー情勢
  • 癌向け精密医療 (プレシジョンメディシン) のITソリューション:C2Aの主な調査結果

第5章 C2Aプロファイル

  • 2bPrecise (Allscripts)
  • Cerner
  • GenomOncology
  • IBM Watson Health
  • N-of-One
  • NantHealth
  • Navican (an Intermountain Healthcare Company)
  • Quest Diagnostics
  • Royal Philips
  • Via Oncology

第6章 結論

第7章 付録

第8章 Frost & Sullivanについて

目次
Product Code: K1E9-48

Early Movers Expect to Facilitate Evidence-Based Cancer Care

Definition:

Precision medicine for oncology is defined as patient-specific cancer care that is aided by a targeted software suite. The realm of precision medicine is determined by providers' willingness and ability to capture and normalize disparate patient data - including clinical, socioeconomic, behavioral, and genomic - to identify evidence-based treatments that are ideal for each patient.

Report Outlook:

This report profiles vendors that are offering promising, disruptive, and pioneering solutions across diverse domains in precision medicine for oncology. It brings the most recent and successful and/or high-potential companies to light. The focus has been to identify vendors that bring in the advantage purely in terms of analytics - not other components of data management and meaningful use. These companies create extraordinary value for their internal and external stakeholders by showcasing visionary leadership and implementing industry best practices, and through business model innovation.

Market Snapshot:

Healthcare IT ecosystems around the world are not adequately equipped to facilitate seamless data interoperability across the care continuum, which is fundamental for enabling precision medicine. For example, even in the United States - arguably a progressive and technologically sophisticated digital health market - the regulatory framework (e.g., CMS, ONC, HHS*) fails to introduce clear mandates that safeguard the privacy of patients willing to share medical data for the Precision Medicine Initiative; outline incentive guidelines for patients accepting precision medicine approaches; introduce reimbursement programs for providers investing in precision medicine systems; and encourage consideration of patients' sociobehavioral state to adjust treatment pathways. As a result, most providers have yet to realize tangible ROIs from precision medicine pilots.

Poor support from ecosystem-level partners (incumbent EHR, RCM, HIE, and clinical decision support system vendors) coupled with a lack of ROI evidence validates that the precision medicine market is still in its infancy.

Despite the low levels of supply-side maturity, more providers will embrace precision medicine, especially in the United States, to improve patient outcomes and rationalize corporate profitability due to mandatory or voluntary involvement in value-based care and the Precision Medicine Initiative. They will depend on external specialist firms to develop proprietary tools or introduce third-party platforms.

Precision medicine IT vendors are going to leverage this renewed market interest to facilitate visionary patient services, supported by the latest clinical and academic evidence.

Key Takeaway:

Top vendors will digitize and automate the process of patient data capture, analysis, and reporting. They will help generate patient-specific treatment options and recommend potential recovery plans based on each patient's clinical and genomic profiles. Physicians will be able to validate these auto-generated clinical pathways based on their experience and knowledge.

Table of Contents

1. EXECUTIVE SUMMARY

  • Global Precision Medicine IT Market Snapshot
  • Global Precision Medicine IT Solutions for Oncology-Analysis of Companies to Action
  • Global Precision Medicine IT Solutions for Oncology-Analysis of Companies to Action (continued)
  • Strategic Imperatives for Industry Stakeholders to Explore Precision Medicine
  • Precision Medicine-Regional Market Overview
  • Key Questions this Study will Answer
  • Precision Medicine-Future Impact on Healthcare
  • Precision Medicine-Strategic Imperatives for Success and Growth

2. COMPANIES TO ACTION OVERVIEW

  • Industry Convergence Driving Disruption and Innovation
  • Convergence in Healthcare Creates Both Opportunities and Threats
  • Frost & Sullivan Companies to Action Have the Potential to Disrupt Current Healthcare Industry Paradigms

3. DIGITAL HEALTH INDUSTRY SNAPSHOT

  • Digital Health Benefits from Broader Industry Convergence
  • Digital Health Priorities
  • Digital Health Market Segmentation and Convergence

4. PRECISION MEDICINE FOR ONCOLOGY MARKET OVERVIEW

  • What is Precision Medicine?
  • Market Challenges, Opportunities, and Concerns
  • Current State of Precision Medicine Adoption
  • Key Data Sources for Precision Medicine
  • Impact of Precision Medicine on Oncology
  • Impact of Key Market Influencers
  • Operational Architecture of Precision Medicine for Oncology
  • Operational Architecture of Precision Medicine for Oncology Explained
  • Stakeholders' Digital Health Solutions
  • Digital Health Solutions Applicable Across the Care Continuum
  • Digital Health Solutions Applicable Across the Care Continuum (continued)
  • Digital Health Solutions Applicable Across the Care Continuum (continued)
  • Digital Health Solutions Applicable Across the Care Continuum (continued)
  • Digital Health Companies Supporting Precision Medicine for Oncology-Vendor Landscape
  • Digital Health Companies Supporting Precision Medicine for Oncology-Vendor Landscape Discussion
  • Digital Health Companies Supporting Precision Medicine for Oncology-Vendor Landscape Discussion (continued)
  • Top Industry Needs and Vendor Strategies
  • Precision Medicine IT Solutions for Oncology-C2A Key Findings

5. C2A PROFILES

  • 2bPrecise (Allscripts)
  • 2bPrecise (Allscripts) (continued)
  • Cerner
  • Cerner (continued)
  • GenomOncology
  • GenomOncology (continued)
  • IBM Watson Health
  • IBM Watson Health (continued)
  • N-of-One
  • N-of-One (continued)
  • NantHealth
  • NantHealth (continued)
  • Navican (an Intermountain Healthcare Company)
  • Navican (an Intermountain Healthcare Company) (continued)
  • Quest Diagnostics
  • Quest Diagnostics (continued)
  • Royal Philips
  • Royal Philips (continued)
  • Via Oncology
  • Via Oncology (continued)

6. THE LAST WORD

  • Precision Medicine-Future Impact on Healthcare
  • Precision Medicine-Strategic Imperatives for Success and Growth
  • Legal Disclaimer

7. APPENDIX

  • List of Vendors Assessed
  • List of Vendors Assessed (continued)
  • List of Vendors Assessed (continued)
  • Abbreviation List

8. THE FROST & SULLIVAN STORY

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top